Clinical trial
FDA Phase IV - Commitment - Retinal Function Study
NCT00461565 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00461565 |
|---|---|
| Title | FDA Phase IV - Commitment - Retinal Function Study |
| Official title | A Double Blind, Randomized, Placebo Controlled, Two Part, Two Session Balanced, Crossover Study to Evaluate Visual Changes in Healthy Male Subjects Aged 18 - 55 Years After Receiving: 1. at Least 15 Doses of 20 mg Vardenafil, Compared to Placebo and 2. Two Doses of Sildenafil, 200 mg Compared to… |
| Lead sponsor | Bayer, Industry |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Safety |
| Intervention type | Drug |
| Interventions | Sildenafil, Placebo, Vardenafil (Levitra, BAY38-9456) |
| Enrollment | 63 |
| Start date | Feb 1, 2005 |
| Completion | Oct 1, 2006 |
| First posted | Apr 18, 2007 |
| Last update posted | Mar 19, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: